DOSIsoft has launched DOSIsoft Theranostics, a dedicated entity focused on developing software for theranostics clinical workflows, ahead of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 annual meeting in Los Angeles.
The new entity is built around Planet, DOSIsoft's flagship theranostics software platform, which has received both CE marking and FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is deployed at hospitals and academic centers worldwide. Planet features voxel-based multiradionuclide dosimetry capabilities and multimodality DICOM interoperability.
DOSIsoft Theranostics will operate as an independent entity within the DOSIsoft group, with its own partnerships and investment strategy, according to the company. DOSIsoft said the dedicated structure is intended to support broader routine clinical adoption of theranostics software as the field expands.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
